RecruitingPhase 2NCT06619561

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Sponsor

Deciphera Pharmaceuticals, LLC

Enrollment

48 participants

Start Date

Nov 21, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Graft-Versus-Host Disease (cGVHD)

Summary

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Vimseltinib for people with chronic graft-versus-host disease (cgvhd). The study is currently recruiting participants at 26 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVimseltinib

Administered orally

Locations(26)

City of Hope National Medical Center

Duarte, California, United States

Ronald Regan UCLA Medical Center

Los Angeles, California, United States

University of California Irvine Health

Orange, California, United States

AdventHealth Orlando

Orlando, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Emory University Winship Cancer Institute

Atlanta, Georgia, United States

University of Illinois Medical Center - Hematology & Oncology

Chicago, Illinois, United States

University of Kansas Cancer Center-Westwood

Westwood, Kansas, United States

University of Kentucky Markey Cancer Center

Lexington, Kentucky, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Henry Ford Cancer Institute

Detroit, Michigan, United States

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Duke University Hospital

Durham, North Carolina, United States

Oncology Hematology Care Clinical Trials, LLC

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Avera Cancer Institute

Sioux Falls, South Dakota, United States

Tristar Bone Marrow Transplant

Nashville, Tennessee, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

St. David's South Austin Medical Center

Austin, Texas, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Intermountain Health

Salt Lake City, Utah, United States

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06619561

Related Trials

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT066603555 locations